Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRSGet Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Trading Up 5.2 %

Shares of PIRS stock opened at $0.18 on Thursday. The company has a market capitalization of $18.28 million, a P/E ratio of -0.53 and a beta of 0.53. Pieris Pharmaceuticals has a 12-month low of $0.14 and a 12-month high of $1.97. The business’s 50 day moving average is $0.18 and its two-hundred day moving average is $0.24.

Pieris Pharmaceuticals (NASDAQ:PIRSGet Free Report) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). Pieris Pharmaceuticals had a negative net margin of 59.25% and a negative return on equity of 98.12%. The business had revenue of $19.52 million for the quarter, compared to analyst estimates of $7.74 million. On average, research analysts predict that Pieris Pharmaceuticals will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. BVF Inc. IL increased its holdings in shares of Pieris Pharmaceuticals by 305.7% during the 2nd quarter. BVF Inc. IL now owns 20,609,863 shares of the biotechnology company’s stock worth $3,411,000 after buying an additional 15,529,543 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Pieris Pharmaceuticals by 589.3% during the fourth quarter. Bank of America Corp DE now owns 3,665,668 shares of the biotechnology company’s stock worth $3,812,000 after buying an additional 3,133,838 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Pieris Pharmaceuticals by 1.6% in the first quarter. BlackRock Inc. now owns 1,338,437 shares of the biotechnology company’s stock valued at $4,055,000 after buying an additional 21,150 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Pieris Pharmaceuticals by 64.8% during the third quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock worth $286,000 after acquiring an additional 378,339 shares during the period. Finally, Silverarc Capital Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth $159,000. 75.03% of the stock is owned by institutional investors and hedge funds.

Pieris Pharmaceuticals Company Profile

(Get Free Report)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Recommended Stories

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.